At the time of writing, Akari Therapeutics Plc ADR [AKTX] stock is trading at $0.39, down -5.02%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AKTX shares have gain 14.87% over the last week, with a monthly amount drifted -28.27%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akari Therapeutics Plc ADR [NASDAQ: AKTX] stock has seen the most recent analyst activity on July 18, 2025, when Maxim Group initiated its Buy rating and assigned the stock a price target of $5. Previously, B. Riley FBR upgraded its rating to Buy on January 04, 2019, and elevated its price target to $3. On February 08, 2018, B. Riley FBR Inc. initiated with a Neutral rating and assigned a price target of $3 on the stock. William Blair upgraded its rating to an Outperform. Chardan Capital Markets upgraded its rating to a Neutral but $6 remained the price target by the analyst firm on May 31, 2017. Chardan Capital Markets reiterated a Sell rating for this stock on April 17, 2017, and downed its price target to $5. In a note dated July 11, 2016, Chardan Capital Markets initiated an Sell rating and provided a target price of $5 on this stock.
For the past year, the stock price of Akari Therapeutics Plc ADR fluctuated between $0.26 and $1.73. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Akari Therapeutics Plc ADR [NASDAQ: AKTX] shares were valued at $0.39 at the most recent close of the market. An investor can expect a potential return of 7592.31% based on the average AKTX price forecast.
Analyzing the AKTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -743.36%, Pretax Profit Margin comes in at -648.51%, and Net Profit Margin reading is -606.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.68 and Total Capital is -0.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3470 points at the first support level, and at 0.3046 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4509, and for the 2nd resistance point, it is at 0.5124.
Ratios To Look Out For
It is important to note that Akari Therapeutics Plc ADR [NASDAQ:AKTX] has a current ratio of 0.19. In addition, the Quick Ratio stands at 0.19 and the Cash Ratio stands at 0.16.
Transactions by insiders
Recent insider trading involved Gaslightwala Abizer, CEO, that happened on Aug 21 ’25 when 10000.0 shares were purchased. CEO, Gaslightwala Abizer completed a deal on Aug 22 ’25 to buy 8000.0 shares. Meanwhile, CEO Gaslightwala Abizer bought 3000.0 shares on Aug 25 ’25.
